Vertex Pharmaceuticals recently reported clinical data showing that CASGEVY helped all evaluable children aged 5–11 with ...
The stock has fallen from a peak back in April.
Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind ...
Zacks Investment Research on MSN
Investors heavily search Vertex Pharmaceuticals Incorporated (VRTX): Here is what you need to know
Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
These companies could innovate their way to success.
Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...
Vertex has achieved significant growth in recent years, but things have slowed lately. The company has many potential catalysts that could accelerate its growth rate. Vertex's pipeline highlights many ...
Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...
With a volume of 1,752,912, the price of VRTX is up 1.48% at $439.58. RSI indicators hint that the underlying stock may be ...
Dec 6 (Reuters) - Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with ...
Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback